Supplementary Figure 1 . Overall DNA methylation patterns in human LCLs. Methylation levels of 72 samples (63 specimens from affected individuals, 2 sets of triplicated un-methylation controls, and 1 set of triplicated methylation controls) after normalization. β was calculated as described in Material and Methods. In general, genomic DNA from human LCLs are hypo-methylated. Red lines represent the triplicated human genomic DNA controls that were artificially hyper-methylated, and green lines represent 2 sets of triplicated human genomic DNA samples that were artificially dermethylated, and blue lines indicate the 63 experimental DNAs from LCLs. X axis is labeled with Log2 [β /(1-β)] .
Supplementary Figure 2 . DNA methylation affects the probability of gene to be expressed in LCLs. A. DNA methylation levels at CpG sites around TSSs affecting gene expression. The overall expression probability for autosomal genes associated with hypomethylated CpG sites around their TSSs is 82.5% (6,571/7,969) , and the overall expression probability for autosomal genes associated with hyper-methylated CpG sites around their TSSs is 36.7% (592/1,615). B. No linear correlation between the DNA methylation and the downstream gene expression observed for CGI CpG sites and non-CGI sites. Each dot represents a CpG-TSS pair. The X-axis and Y-axis respectively indicate the percentile of the DNA methylation level of the CpG site and the expression level of the corresponding gene represented by the CpG -TSS pair. C. Both DNA methylation level and chromosome locations of the CpG sites around TSSs affecting gene expression in female LCLs. For genes associated with hypo-methylated CpG sites, 82.3% autosomal genes and 61.4% X linked genes are expressed, however, autosomal genes are more likely to be expressed (p = 6.0E-06). For genes associated with hyper-mehtylated CpG sites, 36.8% autosomal genes and 44.5% X linked genes are expressed, The probability of expression for both groups is equally reduced (p = 0.08). Hypo-M: hypomethylated CpG sites with Log 2 (β/1-β)<-2; Hyper-M: hypermethylated CpG sites with Log 2 (β/1-β)>0; p was calculated by binomial proportions analysis. Supplementary Figure 3 . DNA methylation affecting cohesin binding to the chromatin in human LCLs. A. The majority of cohesin binds to chromatin regions with low levels of DNA methylation, quantitative raw signal intensity was used to label Y axis to describe the average amount of cohesin bound to chromatin. B. Cohesin preferentially binds to hypomethylated DNA and the increased methylation level prohibits cohesin binding in LCLs quantitatively. Methylation of CpG sites associated to 12,081 genes in 22 controls were analyzed, quantitative cohesin binding signal was obtained from healthy controls in the ChIP-chip assay from our previous study and mapped to each CpG site. Supplementary Figure 4 . Bisulfite sequencing of a 358 bp fragment that is located at LMO2 promoter region in 6 control and 6 CdLS samples. The examined fragment is located on chr11:33,870,140-33,870,497 surrounding probe cg11822932 on the HumanMethylation27 array which is 120 bp upstream of the TSS of LMO2. The LMO2 promoter does not have a CpG island, there are 3 CpG dinucleotides in this tested region. The solid block represents the methylated "C" allele that remains as "C" after bisulfite conversion and the empty block represents the unmethylated "C" allele that was converted to "T" after bisulfite treatment. 10-12 clones were selected for sequencing for each sample. Each row represents on sequenced clone and each column represents one examined "CpG" site. The arrows point to the probe cg11822932.
